The Lynx Group
Cholangiocarcinoma News

Importance of PKN2 Signaling in the Development of Drug Resistance in Patients with CCA and FGFR2 Fusion

2020 Year in Review: Cholangiocarcinoma — December 19, 2020

Preclinical evidence presented at the AACR meeting implicates PKN2 signaling in resistance mechanisms in patients with FGFR2 fusion–positive intrahepatic CCA.

Chemotherapy, radiation, and surgery are all conventional antitumor therapies. After the identification of molecular aberrations as drivers for carcinogenesis, the introduction of therapies targeting specific tumor-promoting pathways has revolutionized the development of cancer therapeutics.

Significant progress has been made in cancer therapy, but oncologists often face the challenge of drug resistance, as many patients with cancer have resistance from the onset of treatment or after initial responses or several treatment cycles. This resistance results in acquired drug resistance and relapses, leading to increased mortality.

Resistance mechanisms in patients with FGFR2 fusion–positive intrahepatic CCA were investigated by Yeonjoo Hwang, BS, Staff Research Associate, University of California, San Francisco, and colleagues. Results were presented at this year’s annual meeting of the American Association for Cancer Research.

FGFR inhibition is associated with the rapid emergence of drug resistance. The mechanisms of FGFR resistance are diverse and include mutations that block drugs from binding to receptor sites. But it is becoming increasingly clear that individual tumors may achieve drug resistance via multiple routes simultaneously based on previous work.

Ms Hwang and colleagues used a phosphoproteomic (ie, a branch of proteomics that identifies, catalogs, and characterizes proteins that contain a phosphate group) analysis of the FGFR2-driven signaling response of a patient-derived FGFR2 fusion–positive intrahepatic CCA with cell line to the FGFR inhibitor TAS-120 (currently in phase 2 clinical trials, in development by Taiho Oncology). They identified a protein kinase, the PKN2, which significantly regulates the sensitivity to inhibition of FGFR fusion and FGFR signaling. PKN2 modulates signaling feedback through the AKT pathway after inhibition of FGFR fusion.

AKT is a key effector in PKN2-mediated FGFR resistance, and its pathway is important. When activated, AKT upregulates the NF-кB pathway, potentially leading to cell survival despite the inhibition of FGFR.

To validate that AKT is the pathway through which the PKN2 is regulating the NF-кB pathway, Ms Hwang and colleagues plan to continue this line of research, which will therefore contribute to drug resistance in patients with CCA and FGFR2 fusion.

Source: Hwang Y, et al. Cancer Res. 2020;80(16_suppl). Abstract 6572.

Related Items

Ivosidenib Approved for Advanced or Metastatic Cholangiocarcinoma
Web Exclusives
Ivosidenib has been approved by the FDA for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma
June/July 2021, Vol 2, No 2
Personalized medicine has expanded the treatment options for patients with cholangiocarcinoma (CCA). At the 2021 Annual Meeting of the Cholangiocarcinoma Foundation (CCF), Ghassan K. Abou-Alfa, MD, MBA, Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, discussed recent developments in personalized therapies, highlighting genomic alterations that are informing the new therapies for patients with CCA.
FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma
June/July 2021, Vol 2, No 2
The FDA granted accelerated approval to the kinase inhibitor infigratinib (Truseltiq) for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) that harbors an FGFR2 fusion or other rearrangement.
Futibatinib in Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements: Primary Results of FOENIX-CCA2 Presented at AACR 2021
June/July 2021, Vol 2, No 2
The primary results of the phase 2 FOENIX-CCA2 clinical trial of futibatinib in patients with previously treated intrahepatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements were presented by Lipika Goyal, MD, MPhil, Assistant Professor of Medicine, Massachusetts General Hospital, Boston, at the 2021 Annual Meeting of the American Association for Cancer Research (AACR).
Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
By Loretta Fala
June/July 2021, Vol 2, No 2
Cholangiocarcinoma (CCA) represents a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine. Although the exact prevalence of CCA is unknown, CCA is a rare cancer; approximately 8000 new cases of CCA are diagnosed annually in the United States.
Incorporating FGFR Inhibitors into the Treatment Paradigm for Cholangiocarcinoma: Current Concepts and Future Directions
By Mitesh J. Borad, MD; Milind M. Javle, MD; Michael Morse, MD, FACP, MHS; Lewis R. Roberts, MB, ChB, PhD
June/July 2021, Vol 2, No 2
On January 15, 2021, experts in the management of patients with cholangiocarcinoma (CCA) convened for a virtual accredited continuing education satellite symposium held during the 2021 annual meeting of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The goal was to educate healthcare providers on various aspects of CCA, including epidemiology, current standards of care, unmet clinical needs, the safety and efficacy of fibroblast growth factor receptor (FGFR) inhibitors as second-line therapy, and practical approaches to incorporating FGFR inhibitors into the treatment paradigm for the disease.
The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
March 2021, Vol 2, No 1
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
Targeted Therapies in Cholangiocarcinoma: Next-Generation Sequencing Is a Must
December 2020, Vol 1, No 3
The recent FDA approval of the first FGFR inhibitor, pemigatinib (Pemazyre), and the positive results from the phase 3 study of the first IDH1 inhibitor, ivosidenib (Tibsovo), represent major breakthroughs in the treatment of patients with cholangiocarcinoma (CCA), a rare cancer associated with poor outcomes. However, the duration of response with these agents is still relatively short.
FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
December 2020, Vol 1, No 3
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: